• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals

  • Print
  • Share
  • E-mail
Generic Name: dasatinib
Trade Name: Phyrago
Date Designated: 10/05/2021
Orphan Designation: Treatment of acute lymphoblastic leukemia
Orphan Designation Status: Designated/Approved
Nanocopoeia, LLC
639 Campus Drive
New Brighton, Minnesota 55112
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

Marketing approved:

1 Generic Name: dasatinib
Trade Name: Phyrago
Marketing Approval Date: 12/05/2023
Approved Labeled Indication: treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy
Exclusivity End Date: TBD  

*Exclusivity Protected Indications are shown for approvals from 01/01/2013 to the present.
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.